Gout is a type of inflammatory arthritis. The disease is triggered by the crystallization of uric acid within the joints and is associated with hyperuricemia, a condition in which the body either overproduces or under excretes uric acid (Choi et al., 2005a). Attacks of gout are episodic in nature and although months may pass before the next attack occurs, the pain experienced during an attack can be debilitating. Men are at a higher risk for developing gout and the risk also increases with age, with a mean age at diagnosis for gout in both men and women of 61 years (Khanna et al., 2012).
This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for gout in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, this report includes a 10-year epidemiological forecast for the diagnosed incident cases and the diagnosed prevalent cases of gout segmented by sex and age (in five-year age groups beginning at 20 years and ending at ≥85 years). The diagnosed prevalent cases are then further segmented by the number of cases of gout flares and tophaceous gout.
To build the epidemiological forecast, GlobalData epidemiologists used country-specific studies that provided the diagnosed incidence and diagnosed prevalence of gout based on the American College of Rheumatology (ACR) criteria for the clinical diagnosis of gout, or diagnostic codes using the International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Oxford Medical Information Systems (OXMIS), or READ (the standard clinical terminology system used in the UK). For the US, GlobalData epidemiologists used the self-reported diagnosed prevalence of gout from the National Health and Nutrition Examination Survey (NHANES) conducted in 2007-2008.
GlobalData epidemiologists forecast an increase in both the diagnosed incident cases and diagnosed prevalent cases of gout in the 6MM, from 1,374,065 diagnosed incident cases in 2013 to 1,649,065 diagnosed incident cases in 2023, at an annual growth rate (AGR) of 2.00%, and 13,750,047 diagnosed prevalent cases in 2013 to 17,625,944 diagnosed prevalent cases in 2023, at an AGR of 2.82%. Throughout the forecast period, the US will have the highest number of diagnosed incident cases and diagnosed prevalent cases of gout, with 949,846 diagnosed incident cases and 11,062,526 diagnosed prevalent cases in 2023.
Comprehensive Table of Contents and more on the report @ http://www.rnrmarketresearch.com/epicast-report-gout-epidemiology-forecast-to-2023-market-report.html .
This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for gout in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, this report includes a 10-year epidemiological forecast for the diagnosed incident cases and the diagnosed prevalent cases of gout segmented by sex and age (in five-year age groups beginning at 20 years and ending at ≥85 years). The diagnosed prevalent cases are then further segmented by the number of cases of gout flares and tophaceous gout.
To build the epidemiological forecast, GlobalData epidemiologists used country-specific studies that provided the diagnosed incidence and diagnosed prevalence of gout based on the American College of Rheumatology (ACR) criteria for the clinical diagnosis of gout, or diagnostic codes using the International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Oxford Medical Information Systems (OXMIS), or READ (the standard clinical terminology system used in the UK). For the US, GlobalData epidemiologists used the self-reported diagnosed prevalence of gout from the National Health and Nutrition Examination Survey (NHANES) conducted in 2007-2008.
GlobalData epidemiologists forecast an increase in both the diagnosed incident cases and diagnosed prevalent cases of gout in the 6MM, from 1,374,065 diagnosed incident cases in 2013 to 1,649,065 diagnosed incident cases in 2023, at an annual growth rate (AGR) of 2.00%, and 13,750,047 diagnosed prevalent cases in 2013 to 17,625,944 diagnosed prevalent cases in 2023, at an AGR of 2.82%. Throughout the forecast period, the US will have the highest number of diagnosed incident cases and diagnosed prevalent cases of gout, with 949,846 diagnosed incident cases and 11,062,526 diagnosed prevalent cases in 2023.
Comprehensive Table of Contents and more on the report @ http://www.rnrmarketresearch.com/epicast-report-gout-epidemiology-forecast-to-2023-market-report.html .